natgillin/translations-raw huggingface dataset:
CELSENTRI film-coated tablets are blue coloured with “MVC 25”, “MVC 75”, “MVC 150” or “MVC 300”. 
CELSENTRI filmom obložene tablete su plave s oznakom „MVC 25“, „MVC 75“, „MVC 150“ ili „MVC 300“.
Concomitant Medications 
Istodobno primijenjeni lijekovi
Tell your doctor if you (or your child) are taking any of these medicines. 
Recite svom liječniku ako Vi (ili Vaše dijete) uzimate neki od navedenih lijekova.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
U svakoj frekvencijskoj skupini nuspojave su prikazane redoslijedom od najozbiljnijih prema manje ozbiljnim.
• if you (or your child, if they are the patient) are allergic to maraviroc or to peanut or soya or to any of the other ingredients of CELSENTRI (listed in section 6 ). 
• ako ste Vi (ili Vaše dijete, ako je ono bolesno) alergični na maravirok, kikiriki, soju ili neki drugi sastojak lijeka CELSENTRI (naveden u dijelu 6.).
Clinical results 
Rezultati kliničkih ispitivanja
These reactions included rash, fever, and sometimes organ dysfunction and hepatic failure. 
Navedene reakcije uključivale su osip, vrućicu te ponekad disfunkciju organa i zatajenje jetre.
Pfizer Manufacturing Deutschland GmbH, Betriebsstātte Freiburg, Mooswaldallee 1, 79090 
Pfizer Manufacturing Deutschland GmbH, Betriebsstātte Freiburg, Mooswaldallee 1, 79090 Freiburg, Njemačka.
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART). 
Prijavljeni su slučajevi osteonekroze, posebice kod bolesnika s opće poznatim čimbenicima rizika, uznapredovalom HIV bolešću ili dugotrajnoj izloženosti kombiniranoj antiretrovirusnoj terapiji.
Any inflammatory symptoms should be evaluated and treatment initiated when necessary. 
Svaki simptom upale treba dobro procijeniti i u slučaju potrebe započeti liječenje.
The latter group had markers correlating to low compliance (low and variable drug levels and often a calculated high residual sensitivity score of the OBT). 
Ova skupina bolesnika imala je markere koji ukazuju na lošu suradljivost (niske i varijabilne razine lijeka te često izračunati visoki rezultat rezidualne osjetljivosti OBT).
The pharmacokinetics of maraviroc is dependent on CYP3A5 activity and expression level, which can be modulated by genetic variation. 
Farmakokinetika maraviroka ovisi o aktivnosti i razini ekspresije CYP3A5, na koje mogu utjecati genske varijacije.
Refer to the Package Leaflets of these other medicines for guidance on how to take them. 
Pročitajte upute o drugim lijekovima da biste znali kako ih uzimati.
Immune reconstitution syndrome 
Sindrom ponovnog uspostavljanja imunosti
Maraviroc was evaluated for carcinogenic potential by a 6 month transgenic mouse study and a 24 month study in rats. 
Karcinogenost maraviroka ispitivana je na transgeničnim miševima tijekom 6 mjeseci i na štakorima kroz 24 mjeseca.
The dose limiting adverse reaction was postural hypotension. 
Nuspojava koja je ograničavala dozu bila je posturalna hipotenzija.
Benzodiazepines 
Benzodiazepini
Median peak maraviroc plasma concentrations are attained at 2 hours (range 0.5-4 hours) following single oral doses of 300 mg commercial tablet administered to healthy volunteers. 
Medijan vršne koncentracije maraviroka u plazmi postiže se za dva sata (raspon 0,5-4 sata) nakon jednokratne primjene komercijalne tablete od 300 mg zdravim dobrovoljcima.
However, a significant treatment benefit for maraviroc compared to placebo + OBT was still demonstrated (see Table 7). 
Usprkos tome, prikazana je značajna korist od liječenja maravirokom u odnosu na liječenje kombinacijom placebo + OBT (vidjeti Tablicu 7.).
In vitro and in vivo studies showed that maraviroc has a potential to increase QTc interval at supratherapeutic doses with no evidence of arrhythmia. 
In vitro i in vivo ispitivanja pokazala su da maravirok ima sposobnost produženja QTc intervala u dozama višim od terapijskih, bez podataka o nastanku aritmije.
It may not be excluded that maraviroc can increase the exposure to the P-glycoprotein substrate dabigatran etexilate. 
Ne može se isključiti mogućnost da maravirok može povećati izloženost dabigatran eteksilatu, supstratu za P-glikoprotein.
In vitro studies have shown that maraviroc does not inhibit any of the major renal uptake transporters at clinically relevant concentrations (OAT1, OAT3, OCT2, OCTN1, and OCTN2). 
Ispitivanja in vitro pokazala su da maravirok u klinički relevantnim koncentracijama ne inhibira nijedan od glavnih prijenosnika za unos tvari u bubrezima (OAT1, OAT3, OCT2, OCTN1 i OCTN2).
• increase in liver enzymes (seen in blood test results), which can be a sign of liver problems (see also ‘Liver problems' earlier in section 4). 
• povišenje vrijednosti jetrenih enzima (vidljivo u nalazima krvnih pretraga), koje može biti znak jetrenih tegoba (pogledajte i dio 'Jetrene tegobe' prethodno u dijelu 4.).
There are limited data in patients with hepatitis B and/or C virus co-infection (see section 5.1). 
Ograničeni su podaci u bolesnika s istodobnom infekcijom virusom hepatitisa B i/ili hepatitisa C (vidjeti dio 5.1).
Studies in Adult Patients Co-infected with Hepatitis B and/or Hepatitis C virus 
Ispitivanja u odraslih bolesnika koji su istodobno zaraženi virusom hepatitisa B i/ili hepatitisa C
The pack contains an oral applicator and a bottle adapter. 
Pakiranje sadrži aplikator za usta i nastavak za bocu.
If a child is unable to reliably swallow CELSENTRI tablets, the oral solution (20 mg per mL) should be prescribed (refer to Summary of Product Characteristics for CELSENTRI oral solution). 
Ako nije sigurno da dijete može progutati CELSENTRI tablete, treba propisati oralnu otopinu (20 mg/ml) (vidjeti Sažetak opisa svojstava lijeka za CELSENTRI oralnu otopinu).
Blood and lymphatic system disorders Absolute neutrophil count 
Poremećaji krvi i limfnog sustava Apsolutni broj neutrofila
Hepatobiliary disorders reported in treatment-naïve patients were uncommon and balanced between treatment groups (see section 4.8). 
Hepatobilijarni poremećaji zabilježeni u prethodno neliječenih bolesnika bili su rijetki i podjednako raspoređeni u svim liječenim skupinama (vidjeti dio 4.8).
Fewer patients discontinued maraviroc due to adverse events (15 vs. 49). 
Manje je bolesnika koji su prekinuli uzimati maravirok zbog nuspojava (15 prema 49).
Patients with pre-existing liver dysfunction, including chronic active hepatitis, can have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice. 
Kod bolesnika s od ranije postojećim oštećenjem funkcije jetre, uključujući kronični aktivni hepatitis, primijećena je povećana učestalost poremećaja jetrene funkcije tijekom primjene kombinirane antiretrovirusne terapije i stoga ih je potrebno nadzirati sukladno standardnoj medicinskoj praksi.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4). 
Prijavljeni su i autoimuni poremećaji (kao što je Gravesova bolest i autoimuni hepatitis); međutim, prijavljeno vrijeme do nastupa bolesti je varijabilnije pa se ti događaji mogu javiti i mjesecima nakon započinjanja liječenja (vidjeti dio 4.4).
Additionally, co-administration of maraviroc with tenofovir (substrate for renal elimination) and cotrimoxazole (contains trimethoprim, a renal cation transport inhibitor), showed no effect on the pharmacokinetics of maraviroc. 
Osim toga, istodobna primjena maraviroka s tenofovirom (izlučuje se bubrezima) i kotrimoksazolom (sadrži trimetoprim, inhibitor transporta kationa u bubrezima) nije dovela do promjene farmakokinetike maraviroka.
The gp120 amino acid substitutions identified so far are context dependent and inherently unpredictable with regards to maraviroc susceptibility. 
Dosad utvrđene aminokiselinske supstitucije gp120 ovise o kontekstu te je njihova povezanost s osjetljivošću na maravirok inherentno nepredvidljiva.
• The other ingredients are: citric acid (anhydrous), sodium citrate dihydrate, sucralose, sodium benzoate, strawberry flavouring (501440T), purified water 
• Drugi sastojci su: citratna kiselina (bezvodna), natrijev citrat dihidrat, sukraloza, natrijev benzoat, aroma jagode (501440T), pročišćena voda Kako CELSENTRI izgleda i sadržaj pakiranja
The symptoms of autoimmune disorders may develop many months after you start taking medicine to treat your HIV infection. 
Simptomi autoimunih poremećaja mogu se razviti mjesecima nakon početka uzimanja lijeka za liječenje HIV-a, a mogu uključivati:
Adult dosage* 
Doza za odrasle*
Insert the applicator (C) firmly into the adapter. 
3. Umetnite aplikator (C) čvrsto u nastavak za bocu.
Overall, the mechanisms of resistance to maraviroc observed in this treatment-experienced paediatric population were similar to those observed in adult populations. 
Sveukupno je mehanizam rezistencije na maravirok opažen u toj prethodno liječenoj pedijatrijskoj populaciji bio sličan onome primijećenom u odraslim populacijama.
Significant reductions in amprenavir Cmin observed may result in virological failure in patients 
Uočena značajna smanjenja Cmin amprenavira kod bolesnika mogu dovesti do neuspješnog virološkog djelovanja.
230 ml oral solution 
230 ml oralne otopine
Baseline CD4+ (cells/µL): 
Početni broj CD4+ (stanice/µl):
The solution is colourless with strawberry flavouring. 
Otopina je bezbojna i ima okus jagode.
Clear, colourless, oral solution. 
Bistra i bezbojna oralna otopina.
In patients with CCR5-tropic virus at time of treatment failure with maraviroc, 22 out of 58 patients had virus with reduced sensitivity to maraviroc. 
Kod bolesnika kod kojih je u trenutku izostanka učinka maraviroka izoliran CCR5-tropni virus, njih 22 od 58 imalo je virus slabije osjetljiv na maravirok.
Effects on active substance levels Geometric mean change if not stated otherwise 
Promjena geometrijske sredine, ako nije drugačije navedeno
HIV-1 variants with reduced susceptibility to maraviroc have been selected in vitro, following serial passage of two CCR5-tropic viruses (0 laboratory strains, 2 clinical isolates). 
In vitro su razvijeni HIV-1 oblici sa smanjenom osjetljivošću na maravirok i to nakon serijske pasaže dva CCR5-tropna virusa (0 laboratorijski sojevi, 2 klinička izolata).
• antibiotics (clarithromycin, telithromycin, rifampicin, rifabutin) 
• antibiotike (klaritromicin, telitromicin, rifampicin, rifabutin)
* Based on drug-drug Interactions (refer to section 4.5) 
*Na temelju interakcija između lijekova (vidjeti dio 4.5)
After intravenous administration (30 mg), the half-life of maraviroc was 13.2 h, 22% of the dose was excreted unchanged in the urine and the values of total clearance and renal clearance were 44.0 L/h and 10.17 L/h respectively. 
Nakon intravenske primjene (30 mg) vrijeme poluživota maraviroka iznosilo je 13,2 h, 22% doze izlučeno je u obliku nepromijenjenog lijeka u urinu, a vrijednosti ukupnog klirensa i bubrežnog klirensa iznosile su 44,0 l/h, odnosno 10,17 l/h.
Limited data exist with the use of maraviroc in patients with severe cardiovascular disease, therefore special caution should be exercised when treating these patients with maraviroc. 
Podaci o primjeni maraviroka kod bolesnika s teškim bolestima kardiovaskularnog sustava su ograničeni, zbog toga je potreban poseban oprez kad se maravirok primjenjuje u liječenju ovih bolesnika.
Hypersensitivity to the active substance or to peanut or soya or to any of the excipients listed in section 6.1. 
Preosjetljivost na djelatnu tvar, kikiriki, soju ili neku od pomoćnih tvari navedenih u dijelu 6.1.
The adverse reactions are listed by system organ class (SOC) and frequency. 
Nuspojave su navedene prema organskim sustavima (SOC) i učestalosti.
Some people taking CELSENTRI have developed severe and life-threatening skin reactions and allergic reactions. 
U nekih osoba koje su uzimale CELSENTRI javile su se teške i po život opasne kožne reakcije i alergijske reakcije.
Population PK analysis in phase 3 studies suggests dose reduction of maraviroc when co-administered with indinavir gives appropriate maraviroc exposure. 
Populacijska PK analiza u ispitivanju faze 3 ukazuje da smanjivanje doze maraviroka pri istodobnoj primjeni s indinavirom, osigurava primjerenu koncentraciju maraviroka.
The Cavg of maraviroc from 24-48 hours for subjects with moderate renal impairment was low (Cavg: 32.8 ng/mL). 
Cavg maraviroka od 24 do 48 sati u bolesnika s umjerenim bubrežnim oštećenjem bila je niska (Cavg : 32,8 ng/ml).
A relatively small number of individuals receiving maraviroc-containing therapy have failed with phenotypic resistance (i.e. the ability to use drug-bound CCR5 with MPI <95%). 
Relativno malen broj osoba liječenih terapijom koja je sadržavala maravirok doživjelo je terapijski neuspjeh zbog fenotipske rezistencije (tj. sposobnosti virusa da koristi CCR5 receptor vezan za lijek uz MPI <95%).
Demographic and Baseline Characteristics 
Demografske značajke i početna obilježja
In patients failing therapy with CCR5-tropic virus only, maraviroc might be considered still active if the MPI value is ≥95% (PhenoSense Entry assay). 
U bolesnika sa samo CCR5-tropnim virusom u kojih je zabilježen terapijski neuspjeh, maravirok se može smatrati i dalje aktivnim ako je MPI ≥95% (PhenoSense Entry test).
Store below 30 °C. 
Čuvati na temperaturi ispod 30ºC.
Discard 60 days after first opening. 
Baciti 60 dana nakon prvog otvaranja.
The absorption of maraviroc is variable with multiple peaks. 
Apsorpcija maraviroka je varijabilna s nekoliko vršnih vrijednosti.
DRUG ABUSE Methadone 
ZLOUPORABA LIJEKOVA Metadon
Maraviroc AUCtau: ↑ 5.00 
Maravirok AUCtau:  5,00
Tropism 
Tropizam
Failure with CXCR4-using virus 
Neuspjeh kod virusa koji koriste CXCR4
A mass balance/excretion study was conducted using a single 300 mg dose of 14C-labeled maraviroc. 
Ispitivanje masene bilance/eliminacije provedeno je primjenom jednokratne doze od 300 mg maraviroka obilježenog 14C-radioaktivnim izotopom.
Wait for the next dose at its regular time. 
Pričekajte i sljedeću dozu uzmite/dajte u za to predviđeno vrijeme.
Cross-resistance in vitro 
Križna rezistencija in vitro
The pack also includes a thermoplastic elastomeric press in bottle adapter, and a 10 ml oral applicator comprised of a polypropylene barrel (with mL graduations) and a polyethylene plunger. 
Pakiranje uključuje i termoplastičan elastomerni nastavak koji se utisne u grlo boce te aplikator za usta volumena 10 ml, koji se sastoji od polipropilenskog tijela (s oznakama za ml) i polietilenskog klipa.
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART). 
Iako se pretpostavlja da nastaje zbog više uzroka (primjena kortikosteroida, konzumacija alkohola, teška imunosupresija, povišeni indeks tjelesne mase), osteonekroza je najčešće uočena kod bolesnika s uznapredovalom bolešću uzrokovanom HIV-om i/ili onih kod kojih je kroz dulje razdoblje primjenjivana kombinirana antiretrovirusna terapija (CART).
There are currently no data regarding the reuse of CELSENTRI in patients that currently have only CCR5-tropic HIV-1 detectable, but have a history of failure on CELSENTRI (or other CCR5 antagonists) with a CXCR4 or dual/mixed tropic virus. 
Za sada još nema podataka koji se odnose na ponovnu primjenu lijeka CELSENTRI kod bolesnika koji trenutno imaju detektabilan samo CCR5-tropni HIV-1, a koji u anamnezi imaju podatak o neuspjehu liječenja lijekom CELSENTRI (ili drugim CCR5 antagonistima) infekcije s CXCR4 ili dvojno/miješano tropnim virusom.
In addition, cholangiocarcinomas (2/60 males at 900 mg/kg) and cholangioma (1/60 females at 500 mg/kg) were reported in the rat study at a systemic exposure at least 15-times the expected free human exposure. 
Dodatno je uočena pojava kolangiokarcinoma (2/60 mužjaka pri dozi od 900 mg/kg) i kolangioma (1/60 ženki pri dozi od 500 mg/kg) u ispitivanju na štakorima kod kojih je sistemska ekspozicija bila najmanje 15 puta viša od očekivane ekspozicije slobodnom lijeku kod ljudi.
Hypersensitivity reactions including severe and potentially life threatening events have been reported in patients taking maraviroc, in most cases concomitantly with other medicinal products associated with these reactions. 
U bolesnika koji su uzimali maravirok prijavljene su reakcije preosjetljivosti, uključujući teške i potencijalno po život opasne događaje, najčešće pri istodobnoj primjeni s drugim lijekovima povezanima s tim reakcijama.
Push the plastic adapter (B) into the neck of the bottle so it is fully inserted. 
Utisnite plastični nastavak (B) u grlo boce cijelom dužinom.
In addition, dosing was based on whether subjects were receiving potent CYP3A inhibitors (38/50), potent CYP3A inducers (2/50) or other concomitant medicinal products that are not potent CYP3A inhibitors or potent CYP3A inducers (10/50) as part of OBT. 
Osim toga, doziranje se temeljilo i na tome jesu li ispitanici u sklopu OBT-a primali snažne inhibitore CYP3A (38/50), snažne induktore CYP3A (2/50) ili druge istodobno primijenjene lijekove koji nisu snažni inhibitori CYP3A ni snažni induktori CYP3A (10/50).
To date, no signature mutation(s) have been identified. 
Zasad nisu pronađene karakteristične mutacije.
Subjects with virologic failure generally appeared to have low compliance to both maraviroc and the background antiretroviral elements of their regimens. 
Čini se da su se ispitanici s virološkim neuspjehom općenito slabo pridržavali i liječenja maravirokom i primjene osnovnih antiretrovirusnih lijekova u svom režimu.
Exposures observed in subjects with severe renal impairment and ESRD were within the range observed in single maraviroc 300 mg dose studies in healthy volunteers with normal renal function. 
Ekspozicije zabilježene u ispitanika s teškim bubrežnim oštećenjem i ESRD kretale su se unutar raspona zabilježenog u ispitivanjima pri primjeni jednokratne doze maraviroka od 300 mg u zdravih dobrovoljaca s normalnom bubrežnom funkcijom.
If a patient is hypersensitive to peanut or soya, CELSENTRI should not be used. 
Bolesnicima preosjetljivima na kikiriki ili soju ne smije se davati CELSENTRI.
In mice, no statistically significant increase in the incidence of tumours was reported at systemic exposures from 7 to 39-times the human exposure (unbound AUC 0-24h measurement) at a dose of 300 mg twice daily. 
Kod miševa nije primijećen statistički značajan porast incidencije pojavljivanja tumora tijekom sistemske ekspozicije 7 do 39 puta veće od ekspozicije kod ljudi (mjerenje AUC 0-24 sata slobodne frakcije) uz dozu od 300 mg dva puta dnevno.
In addition, co-administration of maraviroc with lamivudine/zidovudine showed no effect of maraviroc on lamivudine (primarily renally cleared) or zidovudine (non-P450 metabolism and renal clearance) pharmacokinetics. 
K tome, niti istodobna primjena maraviroka s lamivudinom/zidovudinom nije pokazala utjecaj maraviroka na farmakokinetiku lamivudina (primarno se uklanja putem bubrega) ni zidovudina (ne metabolizira se preko P450 i uklanja se bubrezima).
More patients treated with maraviroc discontinued due to lack of efficacy (43 vs.15) and among patients with lack of efficacy, the proportion acquiring NRTI resistance (mainly lamivudine) was higher in the maraviroc arm. 
Više bolesnika koji su dobivali maravirok prekinulo je liječenje zbog izostanka djelotvornosti (43 prema 15), a među bolesnicima kod kojih nije bilo djelotvornosti više je onih koji su stekli otpornost prema NRTI (uglavnom lamivudin) iz skupine koja je dobivala maravirok.
Subjects received 150 mg of maraviroc at different dose frequencies (healthy volunteers - every 12 hours; mild renal impairment - every 24 hours; moderate renal impairment - every 48 hours). 
Ispitanici su dobivali 150 mg maraviroka različitom učestalošću doziranja (zdravi dobrovoljci - svakih 12 sati; ispitanici s blagim bubrežnim oštećenjem - svaka 24 sata; ispitanici s umjerenim bubrežnim oštećenjem - svakih 48 sati).
When maraviroc was administered in studies with healthy volunteers at doses higher than the recommended dose, cases of symptomatic postural hypotension were seen at a greater frequency than with placebo. 
Kad je maravirok primjenjivan u dozama višim od preporučenih, tijekom studija na zdravim ispitanicima, učestalost simptomatske posturalne hipotenzije bila je veća nego pri primjeni placeba.
In treatment-naïve patients such events occurred at a similarly low rate with maraviroc and control (efavirenz). 
U prethodno neliječenih bolesnika takvi su se događaji javljali s usporedivo niskom stopom kako u skupini liječenoj maravirokom, tako i u kontrolnoj skupini (efavirenz).
The maravirocresistant viruses remained CCR5-tropic and there was no conversion from a CCR5-tropic virus to a CXCR4-using virus. 
Virusi rezistentni na maravirok ostali su CCR5-tropni i nije bilo prijelaza s CCR5-tropnog virusa u virus koji koristi CXCR4.
Depression, insomnia common 
Depresija, nesanica često
When combining rifabutin with protease inhibitors that are potent inhibitors of CYP3A4 a net inhibitory effect on maraviroc is expected. 
Pri kombiniranju rifabutina s inhibitorima proteaza koji su snažni inhibitori CYP3A4 očekuje se čisti inhibitorni učinak na maravirok.
• antifungal medicines (ketoconazole, itraconazole, fluconazole) 
• antimikotike (ketokonazol, itrakonazol, flukonazol)
HIV-1 clinical isolates resistant to NRTIs, NNRTIs, PIs and enfuvirtide were all susceptible to maraviroc in cell culture. 
Klinički izolati HIV-1 rezistentni na NRTI, NNRTI, IP i enfuvirtid u kulturi stanica su bili osjetljivi na maravirok.
ViiV Healthcare BV, Huis ter Heideweg 62, 3705 LZ Zeist, Netherlands. 
ViiV Healthcare BV, Huis ter Heideweg 62, 3705 LZ Zeist, Nizozemska.
Prolongation of the QT interval was seen in dogs and monkeys at plasma concentrations 6 and 12 times, respectively, those expected in humans at the maximum recommended dose of 300 mg twice daily. 
Kod pasa i majmuna je uočeno produljenje QT intervala kod koncentracija u plazmi koje su 6 odnosno 12 puta više od onih očekivanih kod ljudi pri primjeni maksimalne preporučene doze od 300 mg dvaput dnevno.
There may be a risk of suboptimal levels with risk of loss of virologic response and resistance development. 
Postoji rizik subterapijskih koncentracija s posljedičnim gubitkom osjetljivosti virusa i razvojem rezistencije.
The recommended dose of CELSENTRI is 150 mg, 300 mg or 600 mg twice per day depending on other medicines that you are taking at the same time. 
Preporučena doza lijeka CELSENTRI je 150 mg, 300 mg ili 600 mg dva puta na dan, ovisno o ostalim lijekovima koje istodobno primjenjujete.
The initial dose of maraviroc was scaled from adult doses using a body surface area (BSA) of 1.73 m2 to children and adolescent BSA (m2)-based bands. 
Početna doza maraviroka određivala se umanjivanjem doze za odrasle, utvrđene na temelju tjelesne površine od 1,73 m2, prema odgovarajućim kategorijama tjelesne površine za djecu i adolescente (m2).
The oral applicator is provided for accurate measurement of the prescribed dose of oral solution. 
Aplikator za usta služi za točno odmjeravanje propisane doze oralne otopine.
There is limited experience in patients with reduced hepatic function, therefore maraviroc should be used with caution in this population (see sections 4.2 and 5.2). 
Iskustva su ograničena kod bolesnika sa smanjenom funkcijom jetre zbog čega se maravirok treba oprezno primjenjivati u toj populaciji bolesnika (vidjeti dijelove 4.2 i 5.2).
Table 3: Adverse reactions observed in clinical trials or post-marketing 
Tablica 3: Nuspojave zabilježene u kliničkim ispitivanjima ili nakon stavljanja lijeka u promet
It is unknown whether maraviroc is excreted in human milk. 
Nije poznato izlučuje li se maravirok u majčino mlijeko.